-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics shares plummeted 61.5% in pre-market trading after the US Food and Drug Administration declined to approve a drug to treat eye diseases.

Zhitongcaijing·01/02/2026 09:09:06
Listen to the news
Outlook Therapeutics shares plummeted 61.5% in pre-market trading after the US Food and Drug Administration declined to approve a drug to treat eye diseases.